Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

GE HealthCare and Masimo have signed an agreement for the integration of Masimo Signal Extraction Technology (SET) pulse oximetry with the Portrait Mobile wireless and wearable patient monitoring ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

The lawsuit resulted in five of Masimo’s claims being rejected, and a jury being unable to reach agreement on the rest. That will see a new trial held, at a date yet to be set. Masimo got its ...

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its ...

Masimo MASI2.20%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn’t getting a big payday. Bloomberg Law reports that the company was only seeking the statutory minimum ...

Apple convinced a federal jury on Friday that health monitoring tech company Masimo’s smartwatches infringe two of its design patents. The jury, in Delaware, agreed with Apple that Masimo ...

According to a regulatory filing, following a review by outside counsel, on October 24, 2024, the Board of Directors of Masimo (MASI) adopted resolutions to terminate the employment of Masimo’s ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.